Becton, Dickinson and Company (NYSE:BDX) Given New $312.00 Price Target at Barclays

Becton, Dickinson and Company (NYSE:BDX) had its target price upped by Barclays from $305.00 to $312.00 in a research report released on Monday, Benzinga reports. Barclays currently has an overweight rating on the medical instruments supplier’s stock.

Becton, Dickinson and Company Trading Up 0.8 %

Shares of BDX stock opened at $236.60 on Monday. The stock has a market cap of $68.38 billion, a P/E ratio of 52.11, a P/E/G ratio of 1.92 and a beta of 0.45. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32. The business has a fifty day simple moving average of $238.35 and a 200-day simple moving average of $240.12.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the firm posted $2.86 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be issued a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Institutional investors have recently bought and sold shares of the stock. OFI Invest Asset Management purchased a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $27,000. OLD Point Trust & Financial Services N A acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth $29,000. DiNuzzo Private Wealth Inc. purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $30,000. Finally, Scarborough Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $32,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.